Cargando…
Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645408/ https://www.ncbi.nlm.nih.gov/pubmed/37944089 http://dx.doi.org/10.1200/GO.23.00294 |
_version_ | 1785134746867597312 |
---|---|
author | Wilson, Brooke E. Sullivan, Richard Peto, Richard Abubakar, Bello Booth, Christopher Werutsky, Gustavo Adams, Cary Saint-Raymond, Agnes Fleming, Thomas R. Lyerly, Kim Gralow, Julie R. |
author_facet | Wilson, Brooke E. Sullivan, Richard Peto, Richard Abubakar, Bello Booth, Christopher Werutsky, Gustavo Adams, Cary Saint-Raymond, Agnes Fleming, Thomas R. Lyerly, Kim Gralow, Julie R. |
author_sort | Wilson, Brooke E. |
collection | PubMed |
description | Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location. |
format | Online Article Text |
id | pubmed-10645408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-106454082023-11-09 Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting Wilson, Brooke E. Sullivan, Richard Peto, Richard Abubakar, Bello Booth, Christopher Werutsky, Gustavo Adams, Cary Saint-Raymond, Agnes Fleming, Thomas R. Lyerly, Kim Gralow, Julie R. JCO Glob Oncol SPECIAL ARTICLES Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location. Wolters Kluwer Health 2023-11-09 /pmc/articles/PMC10645408/ /pubmed/37944089 http://dx.doi.org/10.1200/GO.23.00294 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | SPECIAL ARTICLES Wilson, Brooke E. Sullivan, Richard Peto, Richard Abubakar, Bello Booth, Christopher Werutsky, Gustavo Adams, Cary Saint-Raymond, Agnes Fleming, Thomas R. Lyerly, Kim Gralow, Julie R. Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title | Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title_full | Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title_fullStr | Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title_full_unstemmed | Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title_short | Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting |
title_sort | global cancer drug development—a report from the 2022 accelerating anticancer agent development and validation meeting |
topic | SPECIAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645408/ https://www.ncbi.nlm.nih.gov/pubmed/37944089 http://dx.doi.org/10.1200/GO.23.00294 |
work_keys_str_mv | AT wilsonbrookee globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT sullivanrichard globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT petorichard globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT abubakarbello globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT boothchristopher globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT werutskygustavo globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT adamscary globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT saintraymondagnes globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT flemingthomasr globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT lyerlykim globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting AT gralowjulier globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting |